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Background: In experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, mice
genetically deficient in the transcription factor signal transducer and activator of transcription 4 (STAT4) are resistant
to disease. In contrast, deletion or inhibition of the Th1-associated cytokines IL-12 or IFNγ which act upstream and
downstream of STAT4, respectively, does not ameliorate disease. These discordant findings imply that STAT4 may
act in a non-canonical role during EAE. Recently, STAT4 has been shown to regulate GM-CSF production by CD4 T
cells and this cytokine is necessary for the induction of EAE. However, it is not known if STAT4 controls GM-CSF
production by both Th1 and Th17 effector CD4 T cells.
Methods: This study utilized the MOG35–55 peptide immunization model of EAE. Intracellular cytokine staining and
novel mixed bone marrow chimeric mice were used to study the CD4 T cell-intrinsic role of STAT4 during disease.
STAT4 chromatin-immunoprecipitation (ChIP-PCR) experiments were performed to show STAT4 directly interacts
with the Csf2 gene loci.
Results: Herein, we demonstrate that STAT4 controls CD4 T cell-intrinsic GM-CSF production by both Th1 and Th17 CD4
T cells during EAE as well as in vitro. Importantly, we show that STAT4 interacts with the Csf2 locus in MOG35–55-activated
effector CD4 T cells demonstrating direct modulation of GM-CSF.
Conclusions: Overall, these studies illustrate a previously unrecognized role of STAT4 to regulate GM-CSF production by
not only Th1 cells, but also Th17 effector CD4 T cell subsets during EAE pathogenesis. Critically, these data highlight for
the first time that STAT4 is able to modulate the effector profile of Th17 CD4 T cell subsets, which redefines our current
understanding of STAT4 as a Th1-centric factor.
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Multiple sclerosis (MS) is a demyelinating autoimmune
disease characterized by the presence of CD4 T cells in
inflammatory lesions within the central nervous system
(CNS) [1, 2]. Studies using the mouse model of MS, ex-
perimental autoimmune encephalomyelitis (EAE), have
demonstrated that the Th1 and Th17 CD4 T cell subsets
are associated with disease onset and that both subsets
are capable of causing disease. Interestingly, while both
Th1 and Th17 cells can initiate disease, the mechanisms
by which these cells mediate inflammation and charac-
teristics of the disease are different [3–5]. For instance,
Th1 cells preferentially migrate to the spinal cord and* Correspondence: lharring@uab.edu
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Th17 cells primarily infiltrate the brain and recruit neu-
trophils. Nevertheless, it is possible that Th1 and Th17
CD4 T cells share properties that contribute to patho-
genicity, and defining these potential commonalities may
lead to new therapeutic targets.
A recent genome-wide association study (GWAS) identi-
fied a polymorphism in the signal transducer and activator
of transcription 4 (STAT4) gene that is associated with MS
susceptibility [6]. STAT4 is a member of the STAT family
of transcription factors and is a Th1 transcriptional regula-
tor [7, 8]. STAT4, when activated by IL-12, results in the
development of Th1 cells and the production of the hall-
mark Th1 cytokine IFNγ. Paradoxically, neither IL-12 nor
IFNγ is required for EAE, while STAT4 is essential. This
highlights an important, unknown function for STAT4ss article distributed under the terms of the Creative Commons Attribution
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the classic Th1 pathway [9–15]. During Th1 differentiation,
STAT4 is necessary to establish the genomic landscape,
which then allows other transcription factors to bind Th1
lineage-associated genes [7, 16, 17]. It remains unclear if
STAT4 instructs the epigenetic landscape in effector CD4
T cells outside of the Th1 lineage. While Th17 differenti-
ation is not contingent on STAT4, the role of this molecule
in Th17 plasticity, and potentially Th17 gene expression,
remains controversial [18–20]. Hence, STAT4 may func-
tion in Th17 cells during EAE, possibly by shaping the ac-
cessibility and expression of encephalogenic genes.
In addition to IFNγ, the Th17 prototypic cytokine IL-
17A is also dispensable for EAE, raising the question as to
how these CD4 T cells mediate disease and if these effector
subsets share an encephalogenic molecule [15, 21]. Both
Th1 and Th17 CD4 T cells produce GM-CSF, which has
been demonstrated to be critical for EAE pathogenesis by
both cell types [22, 23]. GM-CSF functions to activate
microglia within the CNS as well as recruit and stimulate
peripheral macrophages and dendritic cells during EAE
[24, 25]. Recent studies show that STAT4 knockout
(STAT4−/−) T cells had diminished GM-CSF production
[26, 27]. These data suggest that STAT4 may regulate GM-
CSF, which in turn drives the development of EAE. How-
ever, whether STAT4 acts in a CD4 T cell-intrinsic manner
and if STAT4 regulates both Th1 and Th17-derived GM-
CSF production during EAE were not determined.
In this study, we investigated the relationship between
STAT4 and GM-CSF production during EAE. We dem-
onstrate that STAT4 regulates GM-CSF expression by
not only MOG-specific Th1 cells, but also Th17 and a
population of GM-CSF+IFNγ−IL-17A− single-producing
subset of cells during EAE. Coincident with a lineage-
indiscriminate role for STAT4, we find that in vitro
STAT4 functions to promote optimal GM-CSF production
in CD4 T cells activated under non-polarizing, Th0 condi-
tions. Using mixed bone marrow chimeric mice, we show
that CD4 T cell-intrinsic STAT4 expression is important
for GM-CSF production during EAE. Furthermore, STAT4
is able to directly bind to and regulate the Csf2 promoter
in encephalogenic CD4 T cells. Overall, this study illus-
trates that STAT4 directly regulates the transcription of
GM-CSF and highlights a previously unrecognized role for
STAT4 in the function of Th17 cells.
Materials and methods
Mice
C57BL/6J, B6.SJL-Ptprca Pep3b/BoyJ (WT CD45.1), and
B6.129S7-Rag1tm1Mom/J (Rag1−/−) were purchased from
the Jackson Laboratory. B6.STAT4−/− (STAT4−/−) mice
were generously provided by Dr. Mark Kaplan [28].
B6.Ifng/Thy1.1 knock-in mice were described previously
[29]. Both C57BL/6J and B6.Ifng/Thy1.1 knock-in micewere used as wild-type (WT) controls. All animals were
bred and maintained under specific pathogen-free condi-
tions at the University of Alabama at Birmingham accord-
ing to Institutional Animal Care and Use Committee
regulations.
Mixed bone marrow chimeric mice
Mixed bone marrow chimeric mice were generated as pre-
viously described [30]. Rag1−/− mice were irradiated with a
split dose of 1000 rad and reconstituted with CD5-
depleted bone marrow by intravenous injection. The trans-
ferred bone marrow cells were a mixture of 50 % CD45.1
WT bone marrow and 50 % CD45.2 WT bone marrow
(WT:WT) or 50 % CD45.1 WT bone marrow and 50 %
CD45.2 STAT4−/− bone marrow (WT:STAT4−/−). Recipient
mice were maintained on antibiotic water for 6 weeks.
Mice were immunized for EAE 10 weeks following
reconstitution.
EAE induction and clinical scoring
Age and sex matched mice between 8 and 12 weeks of age
were induced for EAE by subcutaneous immunization with
50 μg MOG35−55 peptide (Biosynthesis) emulsified in CFA
(150 μg Mycobacterium tuberculosis; Difco) and intraperi-
toneal (i.p.) administration of pertussis toxin (200 ng; List
Biological Laboratories) on days 0 and 2. Disease was mon-
itored daily by the following criteria: 0, no disease; 1, tail
paralysis; 2.0, hind limb paresis; 3.0, complete hind limb
paralysis; 4.0, forelimbs paralysis; and 5, moribund.
Ex vivo stimulation
Single-cell suspensions of spinal cord, spleen, and inguinal
LNs were prepared as previously described [31]. The
following antibodies were used: anti-CD4 PerCP-Cy5.5/
APC/eFluor 450/PE-Cy7 (eBioscience, clone RM4-5), anti-
CD45.1 FITC (eBioscience, clone A20), anti-CD45.2
PerCP-Cy5.5/APC (eBioscience, clone 104), and anti-CD44
FITC (eBioscience, clone IM7). For intracellular staining,
cells were reactivated with culture media (negative control)
or 5 μM MOG35−55 peptide for 7 h with GolgiPlug (BD
Biosciences) added for the final 4 h. The following intracel-
lular antibodies were used in accordance with the manu-
facturer’s protocols: anti-IFNγ eFluor 450 (eBioscience,
clone XMG1.2), anti-IL17A Alexa Fluor 647 (eBioscience,
clone eBio17B7), anti-GM-CSF PE (BD Biosciences, clone
MP1-22E9). A viability dye (Aqua, Life Technologies) was
applied to exclude dead cells. Samples were acquired by
using an LSRII flow cytometer (BD Biosciences) followed
by data analysis using FlowJo version 9.x (Tree Star).
Naïve CD4 T cell polarization and activation
Naïve CD4+CD25−CD45RBhi (anti-CD25 PerCP-Cy5.5
(eBioscience, clone PC61.5); anti-CD45RB FITC (eBio-
science, clone C363.16A)) T cells were sorted from WTand
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ences) and cultured in the presence of irradiated WT
feeders in R10 containing 2.5 μg/ml anti-CD3 (clone 145-
11) for 5–6 days. Conditions also contained the following:
Non-polarizing (Th0) with anti-IL-12p40—10 μg/ml anti-
IL-12p40 (clone C17.8); Th1—10 ng/ml rmIL-12 and 10
μg/ml anti-IL-4 (clone 11B11); Th17 (TGFβ1)—10 ng/ml
rmIL-23, 20 ng/ml rmIL-6, 5 ng/ml rhTGFβ1, 10 μg/ml
anti-IL-4, and 10 μg/ml anti-IFNγ (clone XMG1.2); Th17
(IL-1β)—10 ng/ml rmIL-23, 20 ng/ml rmIL-6, 5 ng/ml
rmIL-1β, 10 μg/ml anti-IL-4, and 10 μg/ml anti-IFNγ. For
intracellular staining, cells were stimulated with R10 only
(negative control) or platebound anti-CD3 (10 μg/ml)/sol-
uble anti-CD28 (1 μg/ml) for 7 h with GolgiPlug (BD Bio-
sciences) added for the final 4 h. Neutralizing antibodies
were obtained from UAB hybridoma facility.
GM-CSF ELISA
Single-cell suspensions from draining inguinal lymph
nodes were prepared and stimulated with either R10
only or 5 μg MOG35−55 peptide for 16 h. Supernatants
were then collected and assessed for GM-CSF produc-
tion by ELISA (eBioscience).
RNA purification, cDNA synthesis, and real-time PCR
Positively selected CD4 T cells were isolated following
stimulation. RNA collection, cDNA synthesis, and real-
time PCR analysis were performed as described previously




ChIP assays were adapted from previously described
methods [32]. Single-cell suspensions from pooled spleen
and dLN were prepared and reactivated with either R10 or
5 μM MOG35−55 peptide for 5 h. CD4 T cells were puri-
fied, fixed, lysed with T cell lysis buffer (20 mM HEPES,
pH 7.4), 150 mM NaCl, 1.5 mM MgCl2, 2 mM EGTA, 1 %
Triton X-100, 12.5 mM β-glycerophosphate, 10 mM NaF,
1 mM Na3VO4), and then sonicated. Equal amounts of
lysate were pre-cleared with BSA and SS-DNA-blocked
protein A beads. Afterwards, 1/10th volume was removed
and saved as “Input.” The remainder was immunoprecipi-
tated with 4 μg of either STAT4 (Cell Signaling, clone
C46B10) or Ser-2-Pol II CTD (Covance, clone H5) anti-
bodies, and the immune complexes were absorbed with
BSA and SS-DNA-blocked protein A beads (Upstate Cell
Signaling Solutions, Charlottesville, VA). Immunoprecipi-
tated DNA was analyzed by qRT-PCR using Sybr Green
reagents. Primers used for indicated promoter regions are
as follows: Csf2 forward: 5′-GGTCTCCTCAGTGGGAG
TCTGT-3′; Csf2 reverse: 5′-GGGGTTTGGGAGATACT
GAGTG-3′; Ifng forward: 5′-TTTCTGGGCACGTTGACCCT-3′; and Ifng reverse: 5′-ACAGCACAGGGAGCC
TTTGT-3′. Reactions for each sample were performed in
triplicate using an ABI StepOnePlus Detection System
(Applied Biosystems, Foster City, CA) and a PCR protocol
comprising an initial 10-min incubation at 95 °C followed
by 40 cycles of 15 s at 95 °C and 1 min at 60–65 °C. The
raw data were analyzed using StepOnePlus software
(Applied Biosystems), and ΔΔCt values for each gene in
each sample were determined.
Statistical analysis
Unpaired Student’s t test and one-way ANOVA were uti-
lized as indicated and generated by GraphPad Prism 6
(version 6.0e).
Results
STAT4 regulates CD4 T cell production of GM-CSF during
EAE
Th1 and Th17 CD4 T cell subsets are important for indu-
cing and maintaining EAE; however, the cardinal cyto-
kines IFNγ and IL-17A are not required for pathogenesis
[3–5, 15, 21]. Interestingly, the Th1-associated transcrip-
tion factor STAT4 is necessary for EAE independent of
the classical IL-12/IFNγ Th1 pathway, highlighting an un-
known role of STAT4 during EAE [9–15]. In order to in-
vestigate this, we analyzed CD4 T cells from C57BL/6
(WT) and STAT4-deficient (STAT4−/−) mice immunized
for EAE. In agreement with published reports [12, 14], we
find that STAT4−/− mice are resistant to EAE induction
(Fig. 1a). Protection is not a result of increased frequency
or number of Foxp3+ regulatory CD4 T cells (Additional
file 1: Figure S1A). Furthermore, administration of an
anti-IL-10R mAb during EAE did not restore disease
susceptibility in STAT4−/− mice, suggesting that STAT4
regulates EAE pathogenicity via pro-inflammatory mecha-
nisms and not by the increase of anti-inflammatory IL-10
production (Additional file 1: Figure S1B).
Recent reports have indicated that GM-CSF is critical
for EAE induction and is produced by both Th1 and
Th17 subsets [22, 23]. Th1 differentiation is linked to
STAT4, while in vitro Th17 development is independent
of STAT4. Therefore, we postulated that STAT4 regu-
lates Th1, but not Th17, GM-CSF production by effector
CD4 T cells, which in turn determines encephalogeni-
city. To interrogate the regulation of GM-CSF by STAT4
during EAE, cells from the draining lymph nodes (dLN)
were restimulated ex vivo with MOG35−55 peptide at the
onset of disease (Fig. 1b). Both the frequency and num-
ber of GM-CSF+ CD4 T cells were significantly higher
in the WT mice compared to the STAT4−/− mice
(Fig. 1b–d). In addition, GM-CSF secretion as well as
mRNA levels were reduced in the STAT4−/− cells com-
pared to WT cells (Fig. 1e, f ). These results demonstrate
that STAT4 regulates GM-CSF production by MOG-
Fig. 1 STAT4 is required for disease induction and GM-CSF production following EAE immunization. EAE was induced in WT and STAT4−/− mice
by MOG35–55 peptide immunization. a Mice were scored daily for disease severity. b–f Single-cell suspensions were prepared from the dLNs 10
days after EAE immunization and analyzed for GM-CSF production following MOG35–55 restimulation. b Representative plots gated on CD44
hiCD4+
T cells. The cumulative (c) frequencies and (d) numbers of GM-CSF+ CD44hiCD4+ T cells are shown. e GM-CSF levels in culture supernatants were
determined by ELISA. f GM-CSF mRNA expression was assayed in purified CD4 T cells. Data represent three independent experiments with (a) 2–5,
(b–e) 3–6, or (f) 4–5 (pooled) mice in each group (mean ± SD). Student’s t test was performed: *p < 0.05; **p < 0.01; ***p < 0.001
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link between STAT4 and GM-CSF.
Both Th1 and Th17 effector cells require STAT4 for GM-
CSF production
Our data indicate that STAT4 is necessary for robust
GM-CSF production by activated CD4 T cells during
EAE; however, both Th1 and Th17 subsets are capable
of producing GM-CSF [22, 23]. Previous reports have
demonstrated that Th17 cells develop independently of
STAT4 [33], yet the role of STAT4 in regulating GM-
CSF induction by these cells during EAE has not been
investigated. To determine if STAT4 regulation of GM-
CSF is restricted to a specific subset of effector CD4 T
cells, we examined the MOG-specific cytokine response
by CD4 T cells 10 days post EAE induction. In WT
mice, we detected MOG-specific CD4 T cells capable of
producing all combinations of IFNγ, IL-17A, and GM-
CSF (single cytokine producers, double cytokine pro-
ducers, and triple cytokine producers) (Fig. 2a). In mice
lacking STAT4, we observed a significant reduction in
the frequencies and numbers of IFNγ+ single and IFN-
γ+IL-17A+ double-producing CD4 T cells (Fig. 2b, c).
Of note, there was a marked reduction in Th1-likeIFNγ+GM-CSF+ double and IFNγ+IL-17A+GM-CSF+
triple-producing CD4 T cells. Moreover, consistent with
previous reports [26, 27, 33], we did not note any differ-
ences in the IL-17A+ single-producing CD4 T cell popu-
lations between the WT and STAT4−/− mice. However,
cytokine analysis revealed a critical role for STAT4 in
regulating GM-CSF production by Th17 cells as well as
a unique subset of GM-CSF only producing cells; the
frequencies and numbers of MOG-specific CD4 T cells
that were GM-CSF+ single producers and IL-17A+GM-
CSF+ double producers were reduced in the STAT4−/−
mice compared to WT mice (Fig. 3b, c). Taken together,
these data signify that STAT4 does not solely function in
Th1 cells during EAE, but acts broadly in a lineage-
indiscriminant manner.
STAT4 controls GM-CSF production in a cell-intrinsic,
lineage-non-specific manner
STAT4 is important for GM-CSF production by effector
CD4 T cells during EAE [14, 26]; however, these experi-
ments do not define if STAT4 is functioning in a cell-
intrinsic manner. To elucidate the CD4 T cell-intrinsic
role of STAT4 in GM-CSF production, naïve CD4 T cells
from WT and STAT4−/− mice were activated in vitro for
Fig. 2 (See legend on next page.)
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Fig. 2 Th1 and Th17 CD4 T cell production of GM-CSF is dependent on STAT4 during EAE. MOG35–55 specific cytokine production was assessed
in the dLN from WT and STAT4−/− mice 10 days after EAE induction. a Representative plots are gated on CD44hiCD4+ T cells, and either GM-CSF+
(top) or GM-CSF− (bottom) CD4+ T cells. The (b) frequencies and (c) numbers of single, double, and triple cytokine-producing CD44hiCD4+ T cells
are shown. Data represent three independent experiments with 3–5 mice in each group. Student’s t test was performed: ns = not significant;
*p < 0.05; **p < 0.01; ***p < 0.001
Fig. 3 STAT4 regulates GM-CSF production in a cell-intrinsic, lineage-independent manner. Naïve CD4 T cells from WT and STAT4−/− mice were
activated under the indicated conditions for 6 days and then restimulated to assess GM-CSF production. a Representative GM-CSF staining gated
on CD44hiCD4+ T cells for non-polarizing conditions are shown. b Publically available RNA-seq tracks comparing Csf2 transcripts from WT [Geo:
GSM994535] and STAT4−/− [Geo: GSM994536] Th1 polarized cells, visualized using the IGV genome browser MM9 mouse gene database [17].
Arrows indicates gene direction. c–d Representative GM-CSF staining gated on CD44hiCD4+ T cells from c Th1 polarized and d Th17 polarized
cells. e The ratio of GM-CSF+ CD44hiCD4+ T cells in the WT versus STAT4−/− cultures was quantitated. Data represent three independent
experiments (mean ± SD). One-way ANOVA with Tukey’s multiple comparisons test was performed: **p < 0.01
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population of GM-CSF+ cells was noted in the WT CD4
T cell cultures, and there was a consistent twofold re-
duction in the frequency of GM-CSF+ CD4 T cells if the
cells lacked STAT4, indicating this molecule is operating
intrinsically to CD4 T cells to regulate GM-CSF (Fig. 3a).
Interestingly, our data suggests that under these condi-
tions, STAT4 is not functioning downstream of IL-12 or
IL-23, two cytokines associated with EAE and known to
activate STAT4 [9–11, 34–37], as neutralization of IL-
12/IL-23p40 had no impact on the in vitro differenti-
ation of GM-CSF+ cells (Fig. 3a).
Th1 cells can be differentiated in vitro by the addition
of IL-12, which subsequently signals via STAT4. To test
the requirement of STAT4 for GM-CSF production by
this subset of effector cells, naïve CD4 T cells from WT
and STAT4−/− mice were activated in vitro under Th1
polarizing conditions. Previously published and publi-
cally available data (GSE40463) indicated differences be-
tween Th1 polarized WT and STAT4−/− CD4 T cells in
Csf2 RNA transcripts (Fig. 3b) [17]. Consistent with their
data, we detected the highest amount of GM-CSF pro-
duction by WT Th1 cells, and this was almost entirely
STAT4 dependent, with a sixfold reduction in GM-CSF+
cells noted (Fig. 3c, e).
The generation of traditional Th17 cells in vitro with
TGFβ1, IL-6, and IL-23 promotes effector cells that pro-
duce lower levels of GM-CSF and are less encephalo-
genic upon adoptive transfer compared to alternative
Th17 cells differentiated in the presence of IL-1β, IL-6,
and IL-23 [38, 39]. Hence, the Th17 polarizing condi-
tions employed can impact the propensity of these cells
to secrete GM-CSF. Traditional Th17 cells (TGFβ1) pro-
duced minimal GM-CSF regardless of the presence of
STAT4 (Fig. 3d). In contrast, alternative Th17 cells (IL-
1β) had increased frequencies of GM-CSF+ cells, and
these cells were dependent on STAT4 signaling, as
STAT4−/− CD4 T cells consistently showed a twofold re-
duction in the frequency of GM-CSF+ cells (Fig. 3d, e).
Together, these in vitro studies indicate that STAT4
functions in both a CD4 T cell-intrinsic and lineage-
non-specific manner.
To verify that STAT4 operates in a CD4 T cell-
intrinsic mode to regulate GM-CSF production during
EAE, we generated mixed bone marrow chimeric mice
consisting of 50 % CD45.1 WT bone marrow and 50 %
CD45.2 STAT4−/− bone marrow. We also made mixed
bone marrow chimeric mice with 50 % CD45.1 WT
bone marrow and 50 % CD45.2 WT bone marrow for
control purposes. Both cohorts of mice demonstrated
similar disease onset and severity following EAE induc-
tion (Fig. 4a). At the peak of EAE disease, day 17, cells
from the spinal cords of diseased mice were assayed for
GM-CSF, as well as IFNγ and IL-17A production, byCD45.2+ CD4 T cells after ex vivo MOG35−55 peptide re-
stimulation. Similar to the intact mice, we observed an ap-
preciable population of WT GM-CSF+ CD4 T cells;
however, the frequency of STAT4−/− CD4 Tcells producing
GM-CSF was markedly reduced (Fig. 4b, c). There was also
a significant decrease in the percentage of STAT4−/− CD4
T cells that were IFNγ+GM-CSF+ double producers and
IFNγ+IL-17A+GM-CSF+ triple producers. We noted a de-
cline in the frequency of STAT4−/− CD4 T cells co-
producing IL-17A and GM-CSF; however, this did not
reach statistical significance. Interestingly, we did detect an
increase in the proportion of STAT4−/− CD4 T cells produ-
cing IL-17A only, which further emphasizes a previously
undescribed role for STAT4 in regulating Th17 function,
including the modulation of GM-CSF levels in these cells.
STAT4 directly interacts with the Csf2 locus to activate
transcription
Both in vitro and in vivo, we find that STAT4 signaling
is critical for optimal lineage-non-specific GM-CSF ex-
pression; however, these data do not reveal if STAT4 is
acting directly to modify the Csf2 locus and/or activate
gene transcription. The Csf2 upstream promoter region
is highly conserved between mouse and human, and sev-
eral predicted STAT4 binding sites are present in this re-
gion [40]. Further, publically available data (GSE40463)
assessing the binding of p300 in WT and STAT4−/− Th1
polarized cells indicate that STAT4 regulates several en-
hancer regions around the Csf2 locus, suggesting that
STAT4 has direct effects on the production of GM-CSF
(Fig. 5a) [17]. To determine if STAT4 is directly regulat-
ing GM-CSF, we performed ChIP analysis of the 1000 bp
region upstream of Csf2 promoter which has predicted
STAT4 binding sites (Fig. 5b). WT and STAT4−/− mice
were immunized for EAE, and on day 10, CD4 T cells
from the spleen and dLN were pooled and activated with
the MOG35−55 peptide for 5 h. This short period of anti-
gen reactivation is sufficient to induce transcription of
cytokine genes prior to the onset of cell proliferation.
Using ChIP-PCR, we detected significant induction of
STAT4 binding to the Csf2 promoter in the WT CD4 T
cells stimulated with the MOG peptide compared to un-
stimulated CD4 T cells (Fig. 5c). As anticipated, STAT4
binding to the Ifng promoter was also increased after
MOG stimulation in WT CD4 T cells and no STAT4
binding to the Csf2 or Ifng promoters was noted in
STAT4−/− CD4 T cells. Importantly, Pol II binding to the
Csf2 promoter was increased in WT CD4 T cells follow-
ing MOG stimulation, but induction of Pol II binding
was not observed in STAT4−/− CD4 T cells, indicating
that transcription of the Csf2 gene is reduced in the ab-
sence of STAT4 (Fig. 5d). Taken together, these data in-
dicate that STAT4 functions to promote GM-CSF
production via a direct interaction with the Csf2 locus.
Fig. 4 CD4 T cell-intrinsic expression of STAT4 is critical for production of GM-CSF during EAE. EAE was induced in WT:WT and WT:STAT4−/− mixed
bone marrow chimeric mice. a Mice were scored daily for disease severity. b–c Spinal cord infiltrating lymphocytes were restimulated with
MOG35–55 peptide and analyzed for IFNγ, IL-17A, and GM-CSF production. b Representative plots are gated on CD4+CD45.2+ T cells as well as
GM-CSF+ (top) or GM-CSF− (bottom) cells. c The cumulative frequencies of IFNγ, IL-17A, and GM-CSF single, double, and triple cytokine-producing
CD4+CD45.2+ T cells are shown. Data represent 2–7 independent experiments with (a) 3–5 or (b–c) 4–5 mice in each group (mean ± SD).
Student’s t test was performed: ns = not significant; *p < 0.05; **p < 0.01
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STAT4 is a transcription factor necessary for the differen-
tiation of the Th1 lineage of effector CD4 T cells [7, 8].
However, while STAT4 is critical for EAE, neither the up-
stream STAT4 activating cytokine IL-12 nor the down-
stream Th1 effector cytokine IFNγ are needed for disease
induction [9–15]. This implicates a role for STAT4 outside
of the traditional Th1-associated IL-12 signaling pathway.
We find that, when activated in vitro under non-
polarizing conditions, the absence of STAT4 results in the
decreased ability of CD4 T cells to produce GM-CSF,
whereas blocking IL-12 has minimal effect on GM-CSF
production by CD4 T cells. This is consistent withpublished data, as well as the data presented herein, show-
ing CD4 T cell production of GM-CSF during EAE is in-
dependent of IL-12 signaling but dependent on STAT4
expression. Our findings do not negate the ability of
IL-12 to induce GM-CSF in a STAT4-dependent man-
ner, but do indicate that additional molecules signal via
STAT4 to promote GM-CSF expression. Taken to-
gether, these data demonstrate STAT4 can function to
regulate GM-CSF separately from the classic Th1 path-
way, particularly during EAE. In keeping with these
data, our study shows a marked decrease in Th1-like
IFNγ+GM-CSF+, Th17-like IL-17A+GM-CSF+, and




Fig. 5 (See legend on next page.)
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Fig. 5 STAT4 interacts with the Csf2 promoter and correlates with activation. a Publically available p300 ChIP-seq tracks from WT [Geo:
GSM994508] and STAT4−/− [Geo: GSM994509] Th1 polarized cells were visualized for the Csf2 gene loci using IGV genome browser mouse MM9
database [17]. Arrows denote gene direction. b Conservation of the Csf2 promoter region between human and mouse. Predicted STAT4 binding
sites are indicated by the green lines. Schematic and data were generated for this region by the rVista2.0 program (http://pipeline.lbl.gov/). c–d
CD4 T cells from the spleens and dLNs of WT and STAT4−/− mice that had been previously immunized for EAE 10 days earlier were stimulated
with MOG35–55 peptide and analyzed by ChIP. c STAT4 and (d) Pol II interactions with the Ifng and Csf2 promoter regions were assessed. Data are
normalized to input control and quantitated relative to media stimulation. Data represent three independent experiments with 4–5 (pooled) mice
in each group (mean ± SD). Student’s t test was performed: ns = not significant; *p < 0.05
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sion in a lineage-indiscriminant manner.
CD4 T cells co-producing IFNγ and IL-17A are
present during EAE and are postulated to be highly
pathogenic [18, 41]. Our interrogation of GM-CSF ex-
pression by effector CD4 T cells revealed that the major-
ity of the IFNγ+IL-17A+ double-producing cells in WT
mice during EAE concurrently express GM-CSF, and
this may explain the pathogenic propensity of this cell
population. The IFNγ+IL-17A+ double-producing cells
have been shown to arise from Th17 CD4 T cells [41],
inferring that the triple cytokine-producing cells are also
derived from plastic Th17 cells. The role of STAT4 in
Th17 plasticity is debatable; the emergence of IFNγ+IL-
17A+ cells from Th17 cells after repeated IL-23 stimula-
tion in vitro has been shown to be both dependent on, as
well as independent of, STAT4 [18, 19]. Interestingly, we
show that STAT4−/− CD4 T cells lack the IFNγ+IL-17A
+GM-CSF+ triple cytokine-producing cell population;
thus, the requirement of STAT4 to induce CNS inflamma-
tion may be linked to Th17 plasticity and the development
of this particular effector cell subset.
The production of IL-17A by Th17 cells has been
shown to be independent of STAT4 and, in fact, we
demonstrate that during EAE, the frequency of IL-17A+
CD4 T cells is actually increased in the absence of
STAT4. One potential explanation for this observation is
the role of STAT4 in modulating expression of the Th1
master transcription factor, Tbet. In the absence of
STAT4, Tbet is induced, but not to the same levels as in
WT CD4 T cells (McWilliams, data not shown). Tbet
can repress IL-17A production [42, 43]; hence, the effect
of STAT4 may be a consequence of lower Tbet levels.
Similarly, the Th1 cytokine IFNγ is able to suppress IL-
17A secretion by CD4 T cells [31, 33] and STAT4 is ne-
cessary for optimal expression of IFNγ [44]; therefore,
the increase in IL-17A+ CD4 T cells may be the result of
diminished autocrine IFNγ signaling. Another possible
reason for the augmented IL-17A frequencies in the ab-
sence of STAT4 is the inability of these cells to undergo
Th17 plasticity [19]. Th17 cells that are unable to con-
vert into IL-17A+IFNγ+, and potentially then IFNγ+
CD4 T cells, may yield higher percentages of these cells
during EAE.Both GM-CSF single and triple cytokine-producing
CD4 T cells were recently described in MS patients [40],
but the ontogeny of these effector cell populations and
how these cells contribute to MS and EAE pathology re-
main unclear. In this study, we show that there is a
marked reduction not only in IFNγ+IL-17A+GM-CSF+
triple-producing CD4 T cells in the absence of STAT4
during EAE, but in all GM-CSF producing effector CD4
T cells. This includes GM-CSF single-producing cells as
well as IL-17A+GM-CSF+ double-producing cells, which
would presumably be Th17 cells. Therefore, STAT4 regu-
lates GM-CSF production in various subsets of effector
CD4 T cells, and the decreased production of GM-CSF by
STAT4−/− CD4 T cells is not solely the result of impaired
Th17 plasticity. It is unclear if the same molecule mediates
the development of these different GM-CSF-producing
CD4 T cell populations. One cytokine shown to regulate
GM-CSF production in mice is IL-23 [22, 23, 45, 46], and
it is interesting to speculate that the impaired GM-CSF
production by STAT4−/− CD4 T cells is linked to defective
IL-23 signaling. Importantly, data from our lab demon-
strates that IL-23-induced STAT3 activation occurs inde-
pendent of STAT4 expression during EAE (McWilliams,
manuscript submitted), indicating that the predominant
IL-23 signaling pathway is intact in the absence of STAT4.
Together, these data suggest that the function of STAT4
in the formation of GM-CSF single, double, and triple
cytokine-producing CD4 T cells may be separate from the
role of IL-23 in the expression of this cytokine during
EAE and that a potentially novel STAT4 ligand drives
CNS inflammation.
We show that during EAE, STAT4 directly interacts
with the Csf2 gene locus to regulate optimal GM-CSF
expression. It is well documented that STAT4 controls
the accessibility of multiple Th1-associated genes; how-
ever, these studies did not highlight GM-CSF as a
STAT4 regulated target [7, 16, 17]. The discrepancies in
these data may reflect differences in the CD4 T cell pop-
ulations examined or the manner in which the cells were
activated; previous reports have studied IL-12-induced
STAT4 gene regulation in differentiating Th1 cells,
whereas we examined the role of STAT4 in GM-CSF
production by bulk effector CD4 T cells during EAE,
which is independent of IL-12. These data imply there
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in vivo during autoimmunity and possibly other inflamma-
tory conditions. Deciphering what these genes are and
which molecules operate via STAT4 to promote gene ex-
pression during disease will be important for dissecting the
underlying causes of autoimmune inflammation.
Our study identifies STAT4 as a potent regulator of
GM-CSF production by effector CD4 T cells of various
lineages. Nevertheless, while GM-CSF levels are signifi-
cantly decreased in STAT4−/− CD4 T cells, this cytokine
is still detectable suggesting that other transcription fac-
tors must mediate expression. Recent publications have
identified both IL-2 and IL-7, signaling via STAT5, as
additional regulators of T cell-derived GM-CSF [40, 47].
This raises an interesting question as to the respective
contributions of STAT4 and STAT5 to GM-CSF expres-
sion and if these molecules act cooperatively to promote
optimal GM-CSF production. One proposed function of
the STAT transcription factors is to modulate the acces-
sibility of lineage-specific genes [7, 16, 17]. Additionally,
STAT4 alters the enhancer landscape around the Csf2
locus [17]. Therefore, a plausible explanation as to how
STAT4 and STAT5 may both regulate GM-CSF is that
STAT4 is controlling the accessibility or optimal tran-
scription conditions of the Csf2 locus for STAT5 in-
volvement. Conversely, STAT5 may be necessary to
open the Csf2 locus in order for STAT4 to then interact,
as we have shown that STAT4 is able to directly bind to
the Csf2 promoter after MOG stimulation. Future stud-
ies will be necessary to address this as well as to deter-
mine if STAT4 expression is critical for the ability of
other transcription factors to bind and promote GM-
CSF production in effector CD4 T cells.Conclusions
This study identifies a previously unrecognized role for
STAT4 to directly bind to the Csf2 promoter and control
GM-CSF expression in CD4 T cells during neuronal in-
flammation. Further, our data challenges the previously
held Th1-centric model of STAT4 activity by demon-
strating that during EAE, STAT4 functions within Th17
cells to modulate GM-CSF levels. Together, our data
suggests that STAT4 may be an attractive therapeutic
target in MS; however, additional research needs to be
performed to assess this possibility.Additional file
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